Investor Relations

Investor Overview

KemPharm uses its LATTM platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.

 

Stock Quote
KMPH (Common Stock)
PriceChange% ChangeVolume
$3.600.000.00%11,075
Previous CloseToday's OpenIntraday HighIntraday Low
$3.60$3.55$3.65$3.55
Exchange: NASDAQ (US Dollar)
09/22/17 12:49 p.m. ET
Refresh quote
Recent NewsMore >>
09/20/17
KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate
09/12/17
KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA
08/31/17
KemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources